{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:35:41Z","timestamp":1792985741815,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-02550-6","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T03:50:43Z","timestamp":1747885843000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of trastuzumab deruxtecan in HER2-positive breast cancer patients with brain metastases after failure of pyrotinib-based therapy"],"prefix":"10.1038","volume":"15","author":[{"given":"Jinmei","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuexue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zefei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2823-7937","authenticated-orcid":false,"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"issue":"5","key":"2550_CR1","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3322\/caac.21634","volume":"70","author":"GM Choong","year":"2020","unstructured":"Choong, G. M., Cullen, G. D. & O\u2019Sullivan, C. C. Evolving standards of care and new challenges in the management of HER2-positive breast cancer. CA Cancer J. Clin. 70(5), 355\u2013374 (2020).","journal-title":"CA Cancer J. Clin."},{"key":"2550_CR2","doi-asserted-by":"publisher","first-page":"102527","DOI":"10.1016\/j.ctrv.2023.102527","volume":"115","author":"V M\u00fcller","year":"2023","unstructured":"M\u00fcller, V. et al. Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature review. Cancer Treat Rev. 115, 102527 (2023).","journal-title":"Cancer Treat Rev."},{"issue":"12","key":"2550_CR3","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari, A. et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann. Oncol. 32(12), 1475\u20131495 (2021).","journal-title":"Ann. Oncol."},{"issue":"1","key":"2550_CR4","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S1470-2045(12)70432-1","volume":"14","author":"T Bachelot","year":"2013","unstructured":"Bachelot, T. et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): A single-group phase 2 study. Lancet Oncol. 14(1), 64\u201371 (2013).","journal-title":"Lancet Oncol."},{"issue":"13","key":"2550_CR5","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1200\/JCO.18.01511","volume":"37","author":"RA Freedman","year":"2019","unstructured":"Freedman, R. A. et al. TBCRC 022: A phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J. Clin. Oncol. 37(13), 1081\u20131089 (2019).","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"2550_CR6","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1200\/JCO.20.00775","volume":"38","author":"NU Lin","year":"2020","unstructured":"Lin, N. U. et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J. Clin. Oncol. 38(23), 2610\u20132619 (2020).","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"2550_CR7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jamaoncol.2022.5610","volume":"9","author":"NU Lin","year":"2023","unstructured":"Lin, N. U. et al. Tucatinib vs Placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases: Updated exploratory analysis of the HER2CLIMB randomized clinical trial. JAMA Oncol. 9(2), 197\u2013205 (2023).","journal-title":"JAMA Oncol."},{"issue":"3","key":"2550_CR8","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S1470-2045(21)00716-6","volume":"23","author":"M Yan","year":"2022","unstructured":"Yan, M. et al. Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): A multicentre, single-arm, two-cohort, phase 2 trial. Lancet Oncol. 23(3), 353\u2013361 (2022).","journal-title":"Lancet Oncol."},{"issue":"7","key":"2550_CR9","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi, S. et al. Trastuzumab Deruxtecan in previously treated HER2-positive breast cancer. N. Engl. J. Med. 382(7), 610\u2013621 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"10390","key":"2550_CR10","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","volume":"401","author":"F Andr\u00e9","year":"2023","unstructured":"Andr\u00e9, F. et al. Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): A randomised, open-label, multicentre, phase 3 trial. Lancet 401(10390), 1773\u20131785 (2023).","journal-title":"Lancet"},{"issue":"10371","key":"2550_CR11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","volume":"401","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz, S. A. et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet 401(10371), 105\u2013117 (2023).","journal-title":"Lancet"},{"issue":"12","key":"2550_CR12","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1158\/2159-8290.CD-22-0837","volume":"12","author":"G Jerusalem","year":"2022","unstructured":"Jerusalem, G. et al. Trastuzumab Deruxtecan in HER2-positive metastatic breast cancer patients with brain metastases: A DESTINY-Breast01 subgroup analysis. Cancer Discov. 12(12), 2754\u20132762 (2022).","journal-title":"Cancer Discov."},{"key":"2550_CR13","doi-asserted-by":"publisher","first-page":"S335","DOI":"10.1016\/j.annonc.2023.09.554","volume":"34","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz, S. A. et al. 377O A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03. Ann. Oncol. 34, S335\u2013S336. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.554 (2023).","journal-title":"Ann. Oncol."},{"issue":"9","key":"2550_CR14","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/s41591-022-01935-8","volume":"28","author":"R Bartsch","year":"2022","unstructured":"Bartsch, R. et al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: A single-arm, phase 2 trial. Nat. Med. 28(9), 1840\u20131847 (2022).","journal-title":"Nat. Med."},{"issue":"1","key":"2550_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/neuonc\/noac144","volume":"25","author":"JM P\u00e9rez-Garc\u00eda","year":"2023","unstructured":"P\u00e9rez-Garc\u00eda, J. M. et al. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial. Neuro Oncol. 25(1), 157\u2013166 (2023).","journal-title":"Neuro Oncol."},{"key":"2550_CR16","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ejca.2023.03.030","volume":"187","author":"I Desmoulins","year":"2023","unstructured":"Desmoulins, I., Bellio, H., M\u00e9jean, N., Truntzer, C. & Ladoire, S. Intracranial response of brain metastases in patients with HER2-amplified breast cancer treated with trastuzumab-deruxtecan after failure of tucatinib-based therapy. Eur. J. Cancer 187, 161\u2013163 (2023).","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"2550_CR17","doi-asserted-by":"publisher","first-page":"101541","DOI":"10.1016\/j.esmoop.2023.101541","volume":"8","author":"SA Im","year":"2023","unstructured":"Im, S. A. et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer. ESMO Open 8(3), 101541 (2023).","journal-title":"ESMO Open"},{"issue":"Suppl 1","key":"2550_CR18","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1093\/oncolo\/oyac009","volume":"27","author":"A Jacobson","year":"2022","unstructured":"Jacobson, A. Trastuzumab Deruxtecan improves progression-free survival and intracranial response in patients with HER2-positive metastatic breast cancer and brain metastases. Oncologist. 27(Suppl 1), S3\u2013S4 (2022).","journal-title":"Oncologist."},{"issue":"10","key":"2550_CR19","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.annonc.2020.06.020","volume":"31","author":"F Montemurro","year":"2020","unstructured":"Montemurro, F. et al. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: Exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial(\u2606). Ann. Oncol. 31(10), 1350\u20131358 (2020).","journal-title":"Ann. Oncol."},{"key":"2550_CR20","unstructured":"Harbeck, N. et al. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: A phase 3b\/4 trial [published correction appears in Nat Med. 30(12):3780 (2024)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02550-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02550-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02550-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T03:50:45Z","timestamp":1747885845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02550-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2550"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-02550-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"30 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This single-center, retrospective cohort study has been approved by the Ethics Committee of the Fifth Medical Center of Chinese People\u2019s Liberation Army General Hospital (approval number: 2021-6-11). All patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"17731"}}